SecurityGLBL / TerraForm Global, Inc. (88104M101)
IndustryElectric Services
Institutional Owners7
Institutional Shares68,849,173 - 39.75%
Shares Outstanding173,192,913 shares (as of 2017-09-30)
Institutional Value$ 21,805,000 USD

Institutional Stock Ownership and Shareholders()

GLBL / TerraForm Global, Inc. Institutional Ownership

TerraForm Global, Inc. (NASDAQ:GLBL) has 7 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 68,849,173 shares. Largest shareholders include Sunedison, Inc., BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., BlackRock Investment Management, LLC, BlackRock Group LTD, Alpine Group Usvi, Llc, and BlackRock Advisors LLC.
TerraForm Global, Inc. (NASDAQ:GLBL) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href=""><img src="" alt="GLBL / TerraForm Global, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-05-01 13F-HR Spot Trading L.L.C 26,602 0 -100.00 105 0 -100.00
2017-02-14 SC 13G/A COOPERMAN LEON G 6,013,155 0 -100.00 0 -100.00
2018-04-26 13F-HR SIMPLEX TRADING, LLC Put 638 0 -100.00 1 0 -100.00
2017-08-14 13F-HR Alpine Group Usvi, Llc 50,000 253
2017-05-01 13F-HR Spot Trading L.L.C Put 0 0
2018-05-16 13F-HR Quad Capital Management Advisors LLC 21,099 0 -100.00 0 0
2017-02-10 13F-HR BlackRock Fund Advisors 2,686,179 3,161,177 17.68 11,040 12,487 13.11
2018-05-11 13F-HR Russell Investments Group, Ltd. 169,000 0 -100.00 858 0 -100.00
2017-02-10 13F-HR BlackRock Advisors LLC 42,841 40,781 -4.81 176 161 -8.52
2017-08-14 13F-HR NUMERIC INVESTORS LLC 330,100 0 -100.00 1,584 0 -100.00
2017-11-09 13F-HR TFS CAPITAL LLC 38,229 0 -100.00 193 0 -100.00
2017-02-10 13F-HR BlackRock Group LTD 170,817 192,080 12.45 702 759 8.12
2017-02-10 13F-HR BlackRock Investment Management, LLC 386,099 386,616 0.13 1,587 1,527 -3.78
2017-02-14 SC 13G SUNEDISON, INC. 63,343,054
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 1,651,561 1,675,465 1.45 6,788 6,618 -2.50

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

A Primer On Brookfield Asset Management

2018-07-09 seekingalpha
Brookfield (BAM), an under-the-radar company, is one of the largest alternative asset managers in the world. (9-2)

Brookfield to sharpen focus on renewable energy sector in India

2018-06-28 livemint
Mumbai: Canada-based Brookfield Asset Management Inc. is looking to increase its focus on renewable energy in India, said two people aware of the firm’s plans, on the condition of anonymity. The asset manager has so far been focussing largely on the real estate and roads segment. (11-0)

Brookfield Renewable Partners' (BEP) CEO Sachin Shah on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Brookfield Renewable Partners L.P. (NYSE:BEP) Q1 2018 Results Earnings Conference Call May 3, 2018 9:00 AM ET (9-1)

CUSIP: 88104M101